amgen

Naturally Splendid Reports Third Quarter Results for 2021

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FSE:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces its unaudited financial results for the nine months ended September 30, 2021. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

Naturally Splendid CEO Mr. Craig Goodwin reports, "The Company continues to execute on our strategic plan developing, manufacturing and distributing plant-based, meat alternative entrees. Having identified plant-based entrees as our priority, work has already begun retrofitting our existing food manufacturing facility located in British Columbia. This includes installation of a state-of-the-art packaging line which has already been initiated. This line is expected to be operational in the next 30 - 45 days. Once fully operational, this new packaging line creates significant opportunities in the retail market by providing a wide range of packaging formats that can then be placed in both chiller and freezer sections of grocery stores. The versatility of this packaging line creates opportunities for sales in multiple formats for different placement in stores across a wide range of potential clients, ultimately resulting in increased sales.

Goodwin adds, "The Company has announced a private placement of which funding will be directed towards the purchase and installation of a high output manufacturing line that will be capable of initially producing a ton an hour output of a wide variety of plant-based entrees. This capacity is expected to increase up to 1,000 kgs to 1,500 kgs per hour within the same manufacturing footprint as efficiencies are achieved.

This line has been selected for the ability to manufacture our plant-based foods to the exacting standards of our Australian partners, Flexitarian Foods. Selection and installation of this manufacturing line is being assisted directly by key members of the Flexitarian Foods team who have travelled from Australia and are currently in the process of their onsite evaluations in order to optimize efficiencies of manufacturing line. Key members of Flexitarian Foods will then also be instrumental in the training of the Naturally Splendid production team to assure our clients that they will be receiving the same high-quality products that are currently produced in Australia".

NATERA Plant Based Food entrees were listed at the British Columbia Institute of Technology (BCIT), the first of what we anticipate to be multiple listings at post-secondary institutions across Canada".

Working with our existing distribution network including Sysco, Gordon Food Service (GFS) and Canex Foods, the Company has representation in major centres across Canada and expects to increase our food service clientele through this network as well as from our own sales initiatives".

The Company has recently announced a direct to consumer, distribution arrangement with Sealand Quality Foods and look to add additional direct to consumer partners to service specific regions and demographics. As consumer shopping habits have changed, driven in large part by the continued challenges posed by the on-going pandemic, additional direct to consumer distribution arrangements will be added to in order to meet the expectations of this growing segment who are adapting to new ways to shop for their groceries.

Naturally Splendid CFO, Mr. Bryan Carson states, "As reported in previous news releases, establishing the new manufacturing and packaging lines in our existing facility requires significantly less capital than would be required to build out an entirely new manufacturing facility. It must also be noted that the ‘learning curve' that is associated with the implementation of a new production line is minimized with the assistance of the Flexitarian Foods team. Manufacturing NATERA Plant Based Foods in Canada rather than importing from Australia will have many advantages including access to ingredients and supplies more readily available in Canada, improved inventory controls and significantly reduced logistic challenges, thus resulting not only in increased margins, but will also bring forth additional opportunities to the Company expanding our current client list, ultimately resulting in improved top and bottom line sales."

Carson further states, "The Company continues to evaluate on-going projects including the Health Canada approved Phase 2 clinical trial for a potential Covid treatment as well as our our bar manufacturing business. In regard to the Health Canada approved clinical trial, we have all been optimistic that the pandemic was on the decline which effected our decisions in how to proceed to trial. However, with the most recent developments surrounding the announcements by the World Health Organization as it relates to the latest mutation of the Covid virus, renewed efforts will be forthcoming looking to partner with experienced pharma companies to get Cavaltinib to trial.

Manufacturing of bars and bites had been a priority up until the pandemic. The bars and bite business has been negatively affected due in part to ingredient supply chain challenges. Challenges related to supply chain logistics needed to be reviewed which required an in-depth evaluation of this division. The Company is developing strategic plans around this opportunity that will allow the Company to begin the recovery of this division. The Company will provide further updates to both the Health Canada trial and the bars and bites manufacturing in the near future."

Financial Reporting Standards.

Naturally Splendid recorded a net loss and comprehensive loss of $2,486,566 for the nine months ended September 30, 2021, compared to a net loss of $3,340,159 during the nine months ended September 30, 2020. The decrease in net loss and comprehensive loss was attributed to the decrease in selling and distribution expenses. Gross profit margins increased by 2.4% of sales in the nine months ended September 30, 2021, compared to the nine months ended September 30, 2020, this is predominately due to the increased profit margins in the new plant-based sales. The Company's sales decreased by approximately $729,000 from the comparative period. During the nine-month period ended September 30, 2021, selling and distribution expense decreased by approximately $512,600 largely due to decreased in production (facility costs, quality assurance and lab testing) and production wages which were offset by the government wage subsidy received during the quarter. Administrative expenses decreased by approximately $431,000 predominantly from office, rent and salaries and corporate promotions. The decrease was attributed to a reduction in investor relations activity due to the pandemic and the reduction of corporate salaries from the government wage subsidy.

Naturally Splendid recorded sales of $619,653 during the nine months ended September 30, 2021, compared to $1,348,831 in for nine months ended September 30, 2020. The Company's sales decreased by approximately $729,000 from the comparative period. The Company had decreased sales in its private label bars and bites business by approximately $694,000 and other branded products decreased by approximately $6,000. Branded hemp products decreased by approximately $83,000 and its Natera Sport products decreased by approximately $130,000. The Company's new Plant-based products had sales of approximately $79,000 during the quarter ended September 30, 2021. During the nine months period ended September 30, 2021, the new Plant-based product sales were approximately $184,000.

Cost of Sales during the nine months ended September 30, 2021, and 2020 were $539,187 and $1,205,901 respectively. The Company gross margin percentage is 13% of sales, during the nine months ended September 30, 2021

The Company continued its sales mix with exports of bulk seed and launching its new plant-based products. The bulk hemp seeds sold at a lower gross margin percentage then compared to the plant-based products and private label sales. The Company is now focused on its higher margin products and new commercial opportunities. Gross profits for the nine months ended September 30, 2021, was $80,466 (13% of sales) compared to $142,930 (11% of sales) for nine months ended September 30, 2020. The best market opportunities for NSE have been both domestic and new international destinations along with Prosnack Natural Foods Inc. private label products.

For the Three Months Ended September 30, 2021For the Three Months Ended September 30, 2020For the Nine Months Ended September 30, 2021For the Nine Months Ended September 30, 2020
$$$$
Statements of Loss Data
Revenue
149,614323,195619,6531,348,831
Cost of sales
(144,375)(292,827)(539,187)(1,205,901)
Gross Profit
5,23930,36880,466142,930
Selling and distribution expenses
(160,991)(246,776)(589,659)(1,102,254)
Administrative expenses
(576,803)(714,191)(1,980,488)(2,411,898)
Other income(loss) and taxes
(735,578)(911,215)(2,486,566)(3,340,159)
Net income (loss)
(735,578)(911,215)(2,486,566)(3,340,159)
Basic and Diluted Earnings (Loss)
Per Share
(0.00)(0.00)(0.01)(0.02)

About Naturally Splendid Enterprises Ltd.

Founded in 2010, NSE operates a food manufacturing facility just outside Vancouver, BC in Canada. The Company has established numerous healthy, functional foods under recognized brands such as Natera Sport™, Natera Hemp Foods, CHII, Elevate Me™ and Woods Wild Bar™, and most recently Natera Plant Based Foods, a line of delicious plant-based meat alternatives for the rapidly growing plant-based market segment. The Company has a myriad of new products and line extensions under development that are approaching launch. NSE, through its joint venture Plasm Pharmaceutical, has been approved for conducting a phase 2 clinical trial approved by Health Canada for treatment of COVID-19. NSE has also developed proprietary technologies for the extraction of high-demand, healthy omega 3 and 6 oils from hemp.

NSE contract manufacturers for healthy, functional food products and ingredients focusing on plant-based ingredients. The Company provides contract manufacturing services for many healthy food companies, private labeling a wide variety of nutritional food products destined for global healthy food markets.

For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-465-0548 (ext. 105)

On Behalf of the Board of Directors
Mr. J. Craig Goodwin CEO, Director

Contact Information

Naturally Splendid Enterprises Ltd.
(NSP - TSX Venture; NSPDF - OTCQB; 50N - Frankfurt)
#108-19100 Airport Way
Pitt Meadows, BC, V3Y 0E2
Office: (604) 465-0548
Fax: (604) 465-1128
E-mail: info@naturallysplendid.com
Website: www.naturallysplendid.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid's control including, Naturally Splendid's ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: Naturally Splendid Enterprises Ltd.



View source version on accesswire.com:
https://www.accesswire.com/675096/Naturally-Splendid-Reports-Third-Quarter-Results-for-2021

News Provided by ACCESSWIRE via QuoteMedia

The Conversation (0)
Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 NASDAQ Biotech Stocks of 2024

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has traded at three-year highs in the first half of 2024 in response to looming interest rate cuts, breakthrough innovations and increased deals in the space.

After dropping to a low of 3,637.05 in October 2023, the index climbed to start 2024 at 4,457.02. It did hit a bump in the road early in Q2 when it plunged to 4,056.3 in April, but it quickly recovered and has since tracked even higher, reaching 4,634.21 on June 24. But while the current economic environment means the biotech sector may have a complex road ahead, robust growth could be in store in the future.

According to a recent report from Precedence Research, the global biotech market is expected to grow at a compound annual growth rate of 11.8 percent from now to 2033, reaching a valuation of US$4.25 trillion.

Keep reading...Show less
Radiopharm Theranostics

First Patient Dosed with PD-L1 Nanobody in Phase 1 Therapeutic Non-Small Cell Lung Cancer Trial

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the therapeutic dosing of the first patient in its Phase 1 clinical trial of RAD 204, a proprietary nanobody which targets Programmed death-ligand 1 (PD-L1)-positive expression in Non-Small Cell Lung Cancer (NSCLC), the most common type of lung cancer.

Keep reading...Show less
Test tubes.

Can AI Help Detect Cancer? Data Analysis Could Open Up Possibilities for Healthcare Industry

Artificial intelligence (AI) has emerged as a valuable tool for solving complex societal issues, and although it's a new industry, its impact is already being felt in key areas of the life science sector.

AI models in healthcare are quickly advancing beyond basic tasks like medical transcription and administrative streamlining; many systems can now effectively analyze extensive genetic data.

By harnessing AI models' ability to identify patterns and make predictions, medical professionals can institute more effective, personalized treatments and develop precision tests to catch diseases earlier.

Keep reading...Show less
Biotech therapy capsule containing DNA strand surrounded by cells.

Top 3 Canadian Biotech Stocks of 2024

Biotech is a dynamic industry that is driving scientific advancements and innovation in healthcare.

According to Grandview Research, the global biotech market was worth US$1.55 trillion in 2023, and the firm expects it to grow at a CAGR of 13.96 percent between 2024 and 2030 to reach a value of US$3.08 trillion.

In Canada, the biotech industry is home to companies pursuing cutting-edge therapies and medical technologies, and the Investing News Network has identified the top three biotech stocks based on their year-on-year gains.

Keep reading...Show less
Radiopharm Theranostics

Investor Webinar – 3pm AEST Tuesday 2 July

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that CEO and Managing Director Riccardo Canevari and Executive Chairman Paul Hopper will conduct an investor webinar to provide an update following announcement of the Company’s $70 million capital raising.

When: 3pm AEST, Tuesday 2 July 2024

Keep reading...Show less
Researcher in medical lab looking at sample with microscope.

Oncology Stocks: 8 Biggest NASDAQ Companies in 2024

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.

Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of the biggest sectors in the life science space. With that in mind, biotechnology and pharmaceutical companies alike are working to develop best-in-class therapeutics for the treatment of various cancers, including lung, breast and prostate cancer.

At this point, their work is far from finished — Fortune Business Insights projects that the global oncology market will increase at a compound annual growth rate of 11.3 percent to reach US$518.25 billion in 2032.

As the global oncology market grows, investors who want exposure to companies working to treat cancer should consider taking a look at biotech and pharma companies with a focus on oncology drugs and testing.

Keep reading...Show less

Latest Press Releases

Related News

×